Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Connor M Blair

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Scientific Reports|April 18, 2024
Disruption of the pro-oncogenic c-RAF-PDE8A complex represents a differentiated approach to treating KRAS-c-RAF dependent PDACSean F Cooke, Thomas A Wright, Yuan Yan Sin, et al.
Molecular Therapy. Oncology|September 2, 2025
Targeting MDM2 homodimer and heterodimer disruption with DRx-098D in <i>TP53</i> wild-type and mutant cancer cellsSean F Cooke, Thomas A Wright, Gillian Lappin, et al.
Peptide Science (Hoboken, N.J.)|February 22, 2021
Stapled ACE2 peptidomimetics designed to target the SARS-CoV-2 spike protein do not prevent virus internalizationDanielle C Morgan, Caroline Morris, Amit Mahindra, et al.
Journal of Translational Autoimmunity|November 24, 2025
Discovery of a PDE4B and PDE4D selective bifunctional degrader for management of chronic inflammatory disordersArvind Shakya, Qiao Liu, Chon Lai, et al.
Plos One|November 18, 2021
Peptides derived from the SARS-CoV-2 receptor binding motif bind to ACE2 but do not block ACE2-mediated host cell entry or pro-inflammatory cytokine inductionAmit Mahindra, Gonzalo Tejeda, Mario Rossi, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Scientific Reports|April 18, 2024
Disruption of the pro-oncogenic c-RAF-PDE8A complex represents a differentiated approach to treating KRAS-c-RAF dependent PDACSean F Cooke, Thomas A Wright, Yuan Yan Sin, et al.
Molecular Therapy. Oncology|September 2, 2025
Targeting MDM2 homodimer and heterodimer disruption with DRx-098D in <i>TP53</i> wild-type and mutant cancer cellsSean F Cooke, Thomas A Wright, Gillian Lappin, et al.
Peptide Science (Hoboken, N.J.)|February 22, 2021
Stapled ACE2 peptidomimetics designed to target the SARS-CoV-2 spike protein do not prevent virus internalizationDanielle C Morgan, Caroline Morris, Amit Mahindra, et al.
Journal of Translational Autoimmunity|November 24, 2025
Discovery of a PDE4B and PDE4D selective bifunctional degrader for management of chronic inflammatory disordersArvind Shakya, Qiao Liu, Chon Lai, et al.
Plos One|November 18, 2021
Peptides derived from the SARS-CoV-2 receptor binding motif bind to ACE2 but do not block ACE2-mediated host cell entry or pro-inflammatory cytokine inductionAmit Mahindra, Gonzalo Tejeda, Mario Rossi, et al.
Pageof 2